Beixin Life and Ying Minda Selected as National Key "Little Giant" Enterprises

Date： 2025-10-20

Recently, the list of the second batch of new key "Little Giant" enterprises, evaluated by the Ministry of Finance and the Ministry of Industry and Information Technology, was announced. Beixin Life and Ying Minda, portfolio companies of Efung Capital, were successfully selected for the list due to their exceptional innovation capabilities and deep technological, joining the ranks of nationally supported key "Little Giant" enterprises.

Key "Little Giant" enterprises are selectively chosen from those already recognized as specialized and sophisticated "Little Giant" enterprises by the MIIT. The application process is more challenging, and the designation carries an implicit "highest-level" status. The selection of Beixin Life and Ying Minda as national key "Little Giant" enterprises signifies that their technological breakthroughs, product innovations, and commercial achievements have received authoritative national recognition.

Previous：Huayuan Wins "Maker in China" InnovationNext：Cell Publishes Xunlu Bio's BCMA CAR-T Re

Related News / Recommended news More

Efung Capital CEO Zhu Pai Attends BIOCHINA 2026: Discussing the New Ecosystem of LP-GP Collaboration

2026 - 03 - 24

In March, Suzhou is gradually embracing the vitality of spring, much like China's biomedical industry, which is gathering momentum amidst transformation. On March 13, during the 11th BioChina Summit (BIOCHINA 2026), Mr. Zhu Pai, CEO of Efung Capital, was invited to attend the core session—the Global Investment Forum—where he engaged in in-depth discussions with industry peers on the theme &quo...

Frontier Biotechnologies Enters Exclusive License Agreement with GSK for siRNA Pipeline Products

2026 - 03 - 25

Frontier Biotechnologies Inc. (“Frontier Biotechnologies” or the “Company”) recently entered into an exclusive licensing agreement with global biopharmaceutical company GlaxoSmithKline (“GSK”). Under the agreement, GSK will obtain exclusive worldwide rights for the development, manufacturing, and commercialization of two siRNA pipeline assets. One candidate drug has reached the Investigational New...

Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio News

2026 - 03 - 06

Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio NewsOn March 5, 2026, the Phase IV clinical study of Oryzogen's recombinant human albumin (rice-derived) Orumin®, evaluating its "safety and efficacy in patients with hypoalbuminemia and/or hypovolemia requiring emergency treatment," achieved its first patient enrollment and completed the init...

Viestar’s Confocal Microscopy Products Selected as Outstanding Domestic Medical Equipment

2026 - 03 - 05

The year 2026 marks the beginning of the 15th Five-Year Plan period. Recently, the 11th batch of the “Outstanding Domestic Medical Equipment Product Catalogue” was officially released. Viestar’s independently developed BIOPSEE® Confocal Laser Endomicroscope and BIOPSEE® Ultra-Thin Probe-based Confocal Laser Endomicroscope were prominently selected. This recognition makes JWS Medical the ...